Stem Cell Cardiomyocyte Differentiation via BMP and Retinoic Acid Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating stem cells into atrial and ventricular cardiomyocytes are hindered by heterogeneity, leading to potential cardiac arrhythmias and inefficiencies in cardiac repair and drug testing, as existing growth factors do not effectively regulate cardiac subtype specification.
Innovation Solution
Inhibiting BMP signaling after mesoderm formation and modulating retinoic acid signaling pathways using agents like Noggin and BMS-189453 to enhance cardiac differentiation efficiency and promote specific cardiomyocyte formation, including ventricular and atrial cardiomyocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current technologies are used to differentiate stem cells into cardiomyocytes, then cardiomyocytes can be produced, but the differentiation is non-specific and results in heterogeneous cell populations
Solution Approach 1:
The patent applies parameter changes by dynamically adjusting signaling pathway activities during differentiation. Specifically, BMP signaling is inhibited after initial differentiation to prevent non-specific cardiac progenitor formation, while retinoic acid signaling is modulated to direct subtype specification. This temporal and functional parameter control enables precise generation of homogeneous ventricular or atrial cardiomyocyte populations rather than heterogeneous mixtures.
2Productivity
If BMP signaling is not inhibited after differentiation initiation, then cardiac progenitors can form, but cardiac differentiation efficiency is reduced
Solution Approach 1:
The patent applies preliminary action by temporarily allowing BMP signaling during early differentiation to establish the cardiac progenitor pool, then inhibiting it at a predetermined stage. This staged approach—first permitting progenitor formation, then blocking further BMP-mediated non-specific differentiation—maximizes both productivity (by ensuring sufficient progenitors) and reliability (by controlling progenitor pool composition).
3Adaptability or versatility
If retinoic acid signaling is not modulated, then cardiac differentiation can proceed, but specific cardiomyocyte subtype formation is limited
Solution Approach 1:
The patent uses retinoic acid signaling as an intermediary to mediate subtype specification decisions. By introducing retinoic acid or its analogs at specific stages, the system directs cardiac progenitors toward either ventricular or atrial fate. This intermediary signaling mechanism provides adaptability (can generate different subtypes) while maintaining manufacturing precision (homogeneous populations of the desired subtype).
Data Source
Figure 1A~1E
Figure 2A~2D
Figure 3A~3C
AI summary
The present invention relates to novel compositions and methods for enhancing cardiac differentiation efficiency of stem cells using a bone morphogenetic protein (BMP) antagonist such as Noggin. The present invention also relates to novel compositions and methods for promoting atrial and ventricular cardiomyocytes formation from stem cells by stimulating or not inhibiting retinoic acid signaling pathway, or by inhibiting retinoic acid signaling pathway in the stem cells, respectively. The present invention further relates to the atrial and ventricular cardiomyocytes formed from the stem cells, and the uses of the cardiomyocytes, e.g., for cardiac injury repairment and screening for new therapeutics for treating cardiac injuries.